Oral Intake of Royal Jelly Has Protective Effects Against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial

Oral Intake of Royal Jelly Has Protective Effects Against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial

<b>Background:</b> Although tyrosine kinase inhibitors (TKIs) are still recommended as the standard therapy in renal cell carcinoma (RCC), the high frequency of adverse events is a weakness of this therapy. Because royal jelly (RJ) possesses anti-inflammatory and antioxidant properties,...

Full description

Bibliographic Details
Main Authors: Kyohei Araki, Yasuyoshi Miyata, Kojiro Ohba, Yuichiro Nakamura, Tomohiro Matsuo, Yasushi Mochizuki, Hideki Sakai
Format: Article
Language:English
Published: MDPI AG 2018-12-01
Series:Medicines
Subjects:
royal jelly
adverse events
tyrosine kinase inhibitors
renal cell carcinoma
double-blinded
randomized clinical trial
Online Access:https://www.mdpi.com/2305-6320/6/1/2

Internet

https://www.mdpi.com/2305-6320/6/1/2

Similar Items